Cerecor Inc. is listed today as Avalo Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $131 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Apr 2017 | $5 M | Private placement after listing | $2 to $10 million | options | SEC | |
| Sep 2016 | $1 M | Private placement after listing | Under $2 million | equity | SEC | |
| Jul 2014 | $16 M | No. 3 | $10 to $50 million | equity, debt, options | SEC | |
| Aug 2013 | $7 M | No. 2 | $2 to $10 million | equity, options | SEC | |
| Mar 2012 | $22 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cerecor Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).
SEC Form D · Apr 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2024
That is all the official record says: Cerecor Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cerecor Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Apple Tree Partners IV, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| ATP III GP, Ltd. | Company | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Isaac Blech | Person | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| MPM Asset Management Investors BV5 LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| MPM Bioventures V GP LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| MPM Bioventures V LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| MPM Bioventures V, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Nea 14 GP, LTD | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| NEA Partners 14, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| New Enterprise Associates 14, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 156 investors.
Largest shareholders today
Institutions holding Avalo Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$80 M9.08%
- BlackRock, Inc.$76 M8.58%
- Farallon Capital Management, L.L.C.$61 M6.87%
- Deep Track Capital, LP$55 M6.24%
- Caligan Partners LP$50 M5.65%
- Affinity Asset Advisors, LLC$50 M5.61%
- TCG Crossover Management, LLC$46 M5.22%
- State Street Corp$39 M4.43%
- Avoro Capital Advisors LLC$36 M4.11%
- Vanguard Capital Management LLC$35 M3.90%
- Nantahala Capital Management, LLC$33 M3.70%
- Price T Rowe Associates Inc /MD/$29 M3.32%
- Bank Of America Corp /de/$27 M3.07%
- Point72 Asset Management, L.P.$25 M2.81%
- Braidwell LP$25 M2.78%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher Sullivan | Executive officer | Apr 2024 |
| Garry Neil, M.D. | Executive officer | Apr 2024 |
| John E Kaiser | Executive officer | May 2017 |
| Mariam E Morris | Executive officer | May 2017 |
| Ronald E Marcus | Executive officer | May 2017 |
| Uli Hacksell | Executive officer | May 2017 |
| John Kaiser | Executive officer | Sep 2016 |
| Mariam Morris | Executive officer | Sep 2016 |
| Ronald Marcus | Executive officer | Sep 2016 |
| Bernadine Heather Fraser | Executive officer | Jul 2014 |
| Blake M. Paterson | Executive officer | Jul 2014 |
| Federica F. O'Brien | Executive officer | Jul 2014 |
| James F. Vornov | Executive officer | Jul 2014 |
| John F. Kaiser | Executive officer | Jul 2014 |
| Reza F. Mazhari | Executive officer | Jul 2014 |
| Sharon F. Rowland | Executive officer | Jul 2014 |
| Karen M. Krumeich | Executive officer | Apr 2012 |
| Reza M. Mazhari | Executive officer | Apr 2012 |
| Sharon M. Rowland | Executive officer | Apr 2012 |
| Aaron Kantoff | Director | Apr 2024 |
| Garry Neil, M.D. | Director | Apr 2024 |
| Gilla Kaplan, Ph.D. | Director | Apr 2024 |
| Jonathan Goldman, M.D. | Director | Apr 2024 |
| June Almenoff, M.D., Ph.D. | Director | Apr 2024 |
| Magnus Persson, M.D., Ph.D. | Director | Apr 2024 |
| Mitchell Chan | Director | Apr 2024 |
| Samantha Truex | Director | Apr 2024 |
| Eugene A. Bauer | Director | May 2017 |
| Isaac A. Blech | Director | May 2017 |
| Magnus E Persson | Director | May 2017 |
| Phil E Gutry | Director | May 2017 |
| Thomas E Aasen | Director | May 2017 |
| Uli Hacksell | Director | May 2017 |
| Behshad Sheldon | Director | Sep 2016 |
| Eugene Bauer | Director | Sep 2016 |
| Isaac Blech | Director | Sep 2016 |
| Magnus Persson | Director | Sep 2016 |
| Phil Gutry | Director | Sep 2016 |
| Thomas Aasen | Director | Sep 2016 |
| Blake M. Paterson | Director | Jul 2014 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.